Status
Conditions
Treatments
About
The purpose of this study is to systematically calculate the mean number of bleeding-only, spotting-only, and bleeding and/or spotting days experienced by a population of reproductive aged,52 mg levonogestrel Intrauterine System(LNG-IUS) users.
Full description
The levonogestrel Intrauterine system (LNG-IUS)(52 mg per 20mg per day release) is associated with medically benign changes to the menstrual pattern. Amenorrhea, the complete cessation of vaginal bleeding for at least 90 consecutive days, is perhaps the most extreme bleeding pattern experienced by some users during the first year. Amenorrhea prevalence is positively associated with duration of use, with approximately 8% of users.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
insertion
Exclusion criteria
Loading...
Central trial contact
Mariam S Lotfy; Ahmed M Alaa eldin, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal